Superparamagnetic Superparticles for Magnetic Hyperthermia Therapy: Overcoming the Particle Size Limit

Abstract

Iron oxide (e.g., Fe$_3$O$_4$ or Fe$_2$O$_3$) nanoparticles are promising candidates for a variety of biomedical applications ranging from magnetic hyperthermia therapy to drug delivery and bio-detection, due to their superparamagnetism, non-toxicity, and biodegradability. While particles of small size (below a critical size, ~20 nm) display superparamagnetic behavior at room temperature, these particles tend to penetrate highly sensitive areas of the body such as the Blood-Brain Barrier (BBB), leading to undesired effects. In addition, these particles possess a high probability of retention, which can lead to genotoxicity and biochemical toxicity. Increasing particle size is a means for addressing these problems but also suppresses the superparamagnetism. We have overcome this particle size limit by synthesizing unique polycrystalline iron oxide nanoparticles composed of multiple nanocrystals of 10 to 15 nm size while tuning particle size from 160 to 400 nm. These so-called superparticles preserve superparamagnetic characteristics and exhibit excellent hyperthermia responses. The specific absorption rates (SAR) exceed 250 W/g (HAC = 800 Oe, f = 310 kHz) at a low concentration of 0.5 mg/mL, indicating their capability in cancer treatment with minimum dose. Our study underscores the potential of size-tunable polycrystalline iron oxide superparticles with superparamagnetic properties for advanced biomedical applications and sensing technologies.